Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition. (IPSAASU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02812134|
Recruitment Status : Unknown
Verified August 2018 by Centre Hospitalier Universitaire, Amiens.
Recruitment status was: Recruiting
First Posted : June 24, 2016
Last Update Posted : August 21, 2018
Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D).
There are no published studies on the role of FGF23 in undernourished anorexic adolescents taking oral phosphorus supplements.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.|
|Study Start Date :||June 2015|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||August 2018|
- FGF23 [ Time Frame: at inclusion and then once a month for 6 months. ]Change in the FGF23 level (U/ml) with regard to the exogenous phosphorus intake (doses of Phosphoneuros®, expressed in mg/kg/day)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02812134
|Contact: Lydia LICHTENBERGER, PhD||+33 3 22 08 76 email@example.com|
|Amiens, France, 80054|
|Contact: Lydia LICHTENBERGER, PhD +33 3 22 08 76 60 firstname.lastname@example.org|
|Principal Investigator:||Lydia LICHTENBERGER, PhD||CHU Amiens|